OBJECTIVE: To determine predictors of mortality and changes in those predictors over time on combination antiretroviral therapy (cART) in South Africa. DESIGN: A cohort study. METHODS: Using routine clinic data with up to 4 years follow-up after antiretroviral therapy initiation and with death ascertainment from a national vital statistics register, we used proportional hazards modeling to assess baseline and time-updated predictors of mortality and changes in strength of those predictors over time on cART. Furthermore, we compared CD4 count among individuals who died by duration on cART. RESULTS: Fifteen thousand sixty subjects (64% men, median CD4 count 127 cells/mm³) started antiretroviral therapy between January 2003 and January 2008. Over a median follow-up of 1.8 years, 2658 subjects died. The baseline characteristics of WHO stage, hemoglobin, CD4 count, HIV RNA level, and symptoms were all associated with mortality during the first 12 months of cART but lost association thereafter. However, time-updated factors of CD4 count, body mass index, symptoms, anemia, and HIV RNA suppression remained strong predictors of death. Most recent CD4 count before death rose from 71 during the first 3 months of cART to 175 cells per cubic millimeter after >3 years of cART. CONCLUSION: Over 4 years of cART, risk of death declined and associations with mortality changed. An increase in CD4 count at death and changing associations with mortality may suggest a shift in causes of death, possibly from opportunistic infections to other infections and chronic illnesses.
OBJECTIVE: To determine predictors of mortality and changes in those predictors over time on combination antiretroviral therapy (cART) in South Africa. DESIGN: A cohort study. METHODS: Using routine clinic data with up to 4 years follow-up after antiretroviral therapy initiation and with death ascertainment from a national vital statistics register, we used proportional hazards modeling to assess baseline and time-updated predictors of mortality and changes in strength of those predictors over time on cART. Furthermore, we compared CD4 count among individuals who died by duration on cART. RESULTS: Fifteen thousand sixty subjects (64% men, median CD4 count 127 cells/mm³) started antiretroviral therapy between January 2003 and January 2008. Over a median follow-up of 1.8 years, 2658 subjects died. The baseline characteristics of WHO stage, hemoglobin, CD4 count, HIV RNA level, and symptoms were all associated with mortality during the first 12 months of cART but lost association thereafter. However, time-updated factors of CD4 count, body mass index, symptoms, anemia, and HIV RNA suppression remained strong predictors of death. Most recent CD4 count before death rose from 71 during the first 3 months of cART to 175 cells per cubic millimeter after >3 years of cART. CONCLUSION: Over 4 years of cART, risk of death declined and associations with mortality changed. An increase in CD4 count at death and changing associations with mortality may suggest a shift in causes of death, possibly from opportunistic infections to other infections and chronic illnesses.
Authors: Maria Cristina Marazzi; Giuseppe Liotta; Paola Germano; Giovanni Guidotti; A Doro Altan; Susanna Ceffa; Massimo Magnano San Lio; Karin Nielsen-Saines; Leonardo Palombi Journal: AIDS Res Hum Retroviruses Date: 2008-04 Impact factor: 2.205
Authors: Dina Hooshyar; Debra L Hanson; Mitchell Wolfe; Richard M Selik; Susan E Buskin; A D McNaghten Journal: AIDS Date: 2007-10-01 Impact factor: 4.177
Authors: Neil A Martinson; Alan Karstaedt; W D Francois Venter; Tanvier Omar; Peter King; Tumi Mbengo; Else Marais; James McIntyre; Richard E Chaisson; Martin Hale Journal: AIDS Date: 2007-10-01 Impact factor: 4.177
Authors: Lara R Fairall; Max O Bachmann; Goedele M C Louwagie; Cloete van Vuuren; Perpetual Chikobvu; Dewald Steyn; Gillian H Staniland; Venessa Timmerman; Mpumelelo Msimanga; Chris J Seebregts; Andrew Boulle; Ralph Nhiwatiwa; Eric D Bateman; Merrick F Zwarenstein; Ronald D Chapman Journal: Arch Intern Med Date: 2008-01-14
Authors: Katherine L Fielding; Salome Charalambous; Amy L Stenson; Lindiwe F Pemba; Des J Martin; Robin Wood; Gavin J Churchyard; Alison D Grant Journal: BMC Infect Dis Date: 2008-07-16 Impact factor: 3.090
Authors: Andreas Jahn; Sian Floyd; Amelia C Crampin; Frank Mwaungulu; Hazzie Mvula; Fipson Munthali; Nuala McGrath; Johnbosco Mwafilaso; Venance Mwinuka; Bernard Mangongo; Paul E M Fine; Basia Zaba; Judith R Glynn Journal: Lancet Date: 2008-05-10 Impact factor: 79.321
Authors: Asgeir Johannessen; Ezra Naman; Bernard J Ngowi; Leiv Sandvik; Mecky I Matee; Henry E Aglen; Svein G Gundersen; Johan N Bruun Journal: BMC Infect Dis Date: 2008-04-22 Impact factor: 3.090
Authors: A B Schwartz; N Tamuhla; A P Steenhoff; K Nkakana; R Letlhogile; T R Chadborn; M Kestler; N M Zetola; S Ravimohan; G P Bisson Journal: Int J Tuberc Lung Dis Date: 2013-10 Impact factor: 2.373
Authors: Mark J Giganti; Paula M Luz; Yanink Caro-Vega; Carina Cesar; Denis Padgett; Serena Koenig; Juan Echevarria; Catherine C McGowan; Bryan E Shepherd Journal: AIDS Res Hum Retroviruses Date: 2015-03-06 Impact factor: 2.205
Authors: Daniel Fuster; Debbie M Cheng; Emily K Quinn; Kaku A Armah; Richard Saitz; Matthew S Freiberg; Jeffrey H Samet; Judith I Tsui Journal: AIDS Date: 2014-04-24 Impact factor: 4.177
Authors: Amit C Achhra; Janaki Amin; Caroline Sabin; Haitao Chu; David Dunn; Lewis H Kuller; Joseph A Kovacs; David A Cooper; Sean Emery; Matthew G Law Journal: AIDS Date: 2012-08-24 Impact factor: 4.177
Authors: Asha R Kallianpur; Quan Wang; Peilin Jia; Todd Hulgan; Zhongming Zhao; Scott L Letendre; Ronald J Ellis; Robert K Heaton; Donald R Franklin; Jill Barnholtz-Sloan; Ann C Collier; Christina M Marra; David B Clifford; Benjamin B Gelman; Justin C McArthur; Susan Morgello; David M Simpson; J A McCutchan; Igor Grant Journal: J Infect Dis Date: 2015-12-21 Impact factor: 5.226
Authors: Christopher J Hoffmann; Michael Schomaker; Matthew P Fox; Portia Mutevedzi; Janet Giddy; Hans Prozesky; Robin Wood; Daniela B Garone; Matthias Egger; Andrew Boulle Journal: J Acquir Immune Defic Syndr Date: 2013-05-01 Impact factor: 3.731
Authors: Christopher J Hoffmann; Silvia Cohn; Fildah Mashabela; Jennifer D Hoffmann; Helen McIlleron; Paolo Denti; David W Haas; Kelly E Dooley; Neil A Martinson; Richard E Chaisson Journal: J Acquir Immune Defic Syndr Date: 2016-01-01 Impact factor: 3.731
Authors: Christopher J Hoffmann; James J Lewis; David W Dowdy; Katherine L Fielding; Alison D Grant; Neil A Martinson; Gavin J Churchyard; Richard E Chaisson Journal: J Acquir Immune Defic Syndr Date: 2013-05-01 Impact factor: 3.731